Cargando…
Cancer vaccines
Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are specific to tumor antigens. The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been shown to be immunogenic...
Autor principal: | Butterfield, Lisa H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707521/ https://www.ncbi.nlm.nih.gov/pubmed/25904595 http://dx.doi.org/10.1136/bmj.h988 |
Ejemplares similares
-
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016
por: Gulley, James L., et al.
Publicado: (2017) -
Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?
por: Butterfield, Lisa H.
Publicado: (2013) -
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities
por: Pardee, Angela D., et al.
Publicado: (2012) -
Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma
por: Naveh, Hadas Prag, et al.
Publicado: (2013) -
Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients
por: Bray, Sarah M., et al.
Publicado: (2011)